Lupin Appoints Abdelaziz Toumi As CEO Of API CDMO Subsidiary

Abdelaziz Toumi’s appointment as CEO of Lupin Manufacturing Solutions is effective from today
Lupin Appoints Abdelaziz Toumi As CEO Of API CDMO Subsidiary

Indian drugmaker Lupin Ltd. appointed Abdelaziz Toumi as chief executive officer of the company’s newly formed subsidiary Lupin Manufacturing Solutions (LMS).

LMS is engaged in the development, manufacture and sale of active pharmaceutical ingredients (API) and is starting to build its contract development and manufacturing operations (CDMO) business, Lupin said in a stock exchange announcement.

The appointment of Toumi, effective from today, is not for a fixed term.

“He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers,” Lupin Managing Director Nilesh Gupta said.

Toumi has over two decades of experience in the biotech, pharma, and contract development and manufacturing operations (CDMO) sectors, spanning Europe, North America, and Asia.

He has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was responsible for driving growth, innovation, and operational excellence.

The Mumbai-based pharma company said Toumi will be based in Switzerland and will spend considerable time in India.

Toumi holds a Doctorate in Chemical Engineering and a Master’s Degree in Business Administration from the University of Southern Queensland, according to the statement.

Lupin has 15 manufacturing sites, seven research centers and more than 20,000 professionals working globally.

(Send feedback to

The Corner Office Journal